• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Enstilar (calcipotriene and betamethasone dipropionate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Enstilar (calcipotriene and betamethasone dipropionate)

  • Profile

Profile

Contact Information

Contact: LEO Pharmaceuticals
Website: https://www.enstilar.com/

Currently Enrolling Trials

    Show More

    General Information

    Enstilar is a dual-action investigational aerosol foam containing calcipotriol, a vitamin D analog, and betamethasone dipropionate, a corticosteroid.

    Enstilar is specifically indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

    Enstilar is supplied as a foam for topical administration. It should be applied to affected areas once daily for up to 4 weeks, and rubbed in gently. Discontinue use when control is achieved. No more than 60 g every 4 days should be used.

    Side Effects

    Adverse effects associated with the use of Enstilar may include, but are not limited to, the following:

    • application site irritation
    • application site pruritus
    • folliculitis
    • skin hypopigmentation
    • hypercalcemia
    • urticaria
    • exacerabation of psoriasis

    Mechanism of Action

    Enstilar is a dual-action investigational aerosol foam containing calcipotriol, a vitamin D analog, and betamethasone dipropionate, a corticosteroid.

    Clinical Trial Results

    The FDA approval was based on two multicenter, randomized, double-blind trials were conducted in subjects with plaque psoriasis.

    Trial One: 302 subjects were randomized to 1 of 3 treatment groups: Enstilar Foam, betamethasone dipropionate in the same vehicle, or calcipotriene hydrate in the same vehicle.

    Trial Two: 426 subjects were randomized to 1 of 2 treatment groups: Enstilar Foam or the vehicle alone. Baseline disease severity was graded using a 5-point Investigator’s Global Assessment (IGA). At baseline subjects scored “Mild”, “Moderate”, or “Severe”.

    The majority of subjects in both trials (76% and 75%) had disease of “Moderate” severity at baseline, 14% and 15% of subjects had disease of “Mild” severity at baseline and 10% of subjects had “Severe” disease at baseline in both trials. The extent of disease involvement assessed by mean body surface area was 7.1% (range 2 to 28%) and 7.5% (range 2 to 30%). In both trials, subjects were treated once daily for up to 4 weeks. Efficacy was assessed with treatment success defined as the proportion of subjects at Week 4 who were “Clear” or “Almost Clear” according to the IGA. The percentage of subjects achieving treatment success is as follows:

    Trial One: Enstilar Foam: 45% verusu Betamethasone dipropionate: 30.7% and callcipotriene: 14.9%.

    Trial Two: Enstilar Foam: 53.3% versus vehicle: 4.8%.

    Approval Date: 2015-10-01
    Company Name: LEO Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing